

Review of Current Dengue Treatment and Therapeutics in Development

Fusco DN^{1*} and Chung RT²

¹Department of Medicine, Massachusetts General Hospital, Boston, MA 02114

²Director of Hepatology, Gastrointestinal Unit-GI Associates, USA

Abstract

Dengue is an arthropod-borne flavivirus associated with hemorrhagic fever and hemorrhagic shock. Roughly one third of the world population lives at risk of dengue infection, and it is not possible to accurately predict which patients are at risk for severe or fatal infection. Currently, there is no treatment for dengue infection. However, several classes of agents are in under investigation as potential anti-dengue drugs, including direct antivirals, host modulators, and RNAi therapeutics. These anti-dengue drugs in development will be reviewed here.

Introduction

Dengue has been named one of the most important emerging infections in 2014 [1,2]. The geographic region at risk for dengue has increased fourfold over the past three decades, unprecedented for a vector-borne disease [2,3]. DENV is an arthropod-borne flavivirus associated with both hemorrhagic fever and hemorrhagic shock [4]. The classical clinical presentation of DENV is characterized by abrupt onset of headache, myalgia and high fever, in addition to arthralgia, retro-orbital pain and hemorrhagic manifestations. The DENV hemorrhagic fever is characterized by fluid leakage into the interstitium. These symptoms are commonly seen in many other infectious diseases, which complicates diagnosis. DENV has also been implicated as a possible cause of multiple findings of end organ failure, including but not limited to: myocardial impairment (with arrhythmias and potential myocarditis), hepatitis with hepatic necrosis, maculopathy, rhabdomyolysis, multiple neurological manifestations, and fatal hemophagocytic lymphohistiocytosis [2,5-14]. 2.5 billion people live in DENV-endemic regions [4], and roughly 400 million infections occur per year with a case fatality rate exceeding 5-20% in some areas [15,16]. Over 100 countries are affected, including Europe and the United States [17]. As effective point of care (POC) diagnostics for malaria reach widespread utilization, the prevalence of non-malarial fevers, caused by dengue (DENV) and other infections, is increasingly noted in low and/or middle income countries (LMICs) [18,19]. DENV is endemic in many parts of Asia, and the DENV case frequency and fatalities in the Americas are increasing, where the total number of DENV cases reported quadrupled between the 1980s and 2000-2007 [7,17,20]. Furthermore, in recent years, infections in many LMICs are increasingly noted in adults, leading to significant number of work days lost and increasing costs to society [21].

Currently there is no specific treatment for DENV, recent hopeful vaccine candidates have just been deemed ineffective [22], and there is no prediction of complete vector control. However, rapid diagnosis followed by targeted vector control efforts decrease DENV transmission, and early detection followed by supportive care is reported to potentially decrease mortality rates from 5-20% to less than 1% [15,16,23]. In many endemic regions, when a surge of dengue infections is suspected, public health authorities will circulate notices in local newspapers, transmits announcements via radio, and even close schools and other public facilities during peaks of transmission in attempts to decrease likely exposure. Other preventive measures include use of insecticide sprays and elimination of all mosquito breeding grounds (areas of standing water are cleared, particularly in schools). While attempts at early diagnosis paired with prevention

are helpful, the combined lack of effective treatment for dengue and increasing dengue transmission are worrisome.

This review will focus on treatments in various stages of development for dengue, organized based on treatment strategy, including direct acting antiviral approaches, RNAi approaches, and host-modulators, and will attempt to complement other recent helpful reviews [5,24]. This review will not cover progress being made toward the challenging fields of DENV vaccine design, vector-targeted interventions, of which there are many, anti-dengue therapeutic antibodies [25], or studies related to precise selection of supportive care measures including choice of resuscitation fluid, corticosteroid administration [26] or platelet transfusion decisions [27,28]. An excellent updated review of DENV vaccine work has recently been published [29]. Additional helpful recent reviews describing DENV treatment strategies under development are cited [5,24,30-32].

Information included in this review was supported by a search of the PubMed database for articles published in the English language using the search term "dengue treatment". In addition, bibliographies of the selected articles were reviewed for further relevant studies.

Methods of Bioanalysis for Anti-dengue Activity

Pre-clinical

Dengue is a positive stranded RNA virus with an 11kb genome, encoding a polyprotein precursor cleaved to generate at least 10 proteins, including three structural proteins (core, membrane associated protein, and envelope protein), and seven nonstructural proteins (NS1, NS2a, NS2b, NS3, NS4b, NS5) (Figure 1) [33]. DENV is transmitted by silent, urban mosquito vectors, including *Aedes aegypti* and *A. albopictus*, *A. polynesiensis* and *A. scutellaris*, to man [3]. Other modes of transmission include via blood products, organ transplant, and vertical transmission [34-37]. There are four serotypes (1-4) of

*Corresponding author: Dahlene Fusco, MD, PhD, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114; E-mail: dnfusco@mgh.harvard.edu.

Received May 02, 2014; Accepted May 29, 2014; Published May 31, 2014

Citation: Fusco DN, Chung RT (2014) Review of Current Dengue Treatment and Therapeutics in Development. J Bioanal Biomed S8: 002. doi:10.4172/1948-593X.S8-002

Copyright: © 2014 Fusco DN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Figure 1: Schematic of the dengue virus polyprotein. The core (c), precursor membrane (prM), and envelope (E) proteins are structural proteins, whereas the remaining 7 proteins are non structural DENV proteins. NS1 is involved in RNA replication, NS2A participates in replication and assembly, NS2B serves as a cofactor for NS3, which is a serine protease, RNA helicase, 5'-RNA triphosphatase, and nucleoside triphosphatase. NS4A and 4B participate in replication, and NS5 serves as a methyl transferase and RNA-dependent RNA polymerase [1,5].

dengue, and multiple genotypes. All four serotypes infect man, and infection with one serotype does not confer protection against another serotype. In contrast, infection with a second dengue serotype appears to be, in some cases, enhanced by pre-existing antibodies generated from primary infection. This phenomenon is referred to as antibody dependent enhancement, or ADE [5,38]. In man, the initial cellular target of dengue is thought to be dendritic cells, followed by lymphatic spread and then distribution to monocytes and macrophages [39,40]. The full host of cells infected *in vivo* remain a subject of investigation, but may also include hepatocytes, myocytes, and other cell types [6,41]. In the laboratory, dengue can be cultivated in C6/36 mosquito cells or Vero African green monkey kidney cells, though intracellular modifications of the virus are thought to differ in these two systems, and are also affected by passage number, and therefore must be monitored [42,43]. Laboratory isolates of dengue can be used to infect several human cell lines, including but not limited to HepaRG human hepatoma cells, Huh7 human hepatoma cells, human foreskin fibroblasts, U937 and THP-1 myeloid cells, HeLa human cervical carcinoma cells [43,44]. In order to infect monocyte cell lines, pre-incubation of virus with anti-dengue antibody can be used to take advantage of antibody dependent enhancement (ADE), which increases the amount of dengue infecting each individual cell [5,38,43].

The level of dengue infectivity can then be monitored *in vitro* by multiple methods, including but not limited to plaque assay, qRT PCR, immunofluorescence, to identify compounds with antiviral activity. In addition to fully infectious dengue systems, *in vitro* reporter systems for dengue have been developed, and are also employed in assays seeking to identify dengue anti-virals [45-49]. The development of animal models of dengue virus (DENV) infection and disease has been challenging, since epidemic DENV does not naturally infect non-human species, but several models now exist, including the AG129 mouse (IFN alpha, beta, gamma knockout mouse), IFNAR1 knockout mouse, STAT2 knockout mouse, and, more recently, humanized BLT mouse [50-52].

Clinical

Clinical methods for evaluation of anti-dengue effects are in development. A major hurdle facing DENV clinical trials is the need for establishment of accurate diagnostic testing for case identification. However, current diagnostics for DENV available in the US and other high resource countries (PCR, IgM and IgG ELISA) are limited by a requirement for skilled workers, refrigeration, and specialized equipment [3,53]. Current point-of-care (POC) diagnostic tests for DENV are based on lateral flow detection of secreted DENV NS1 protein and IgM in blood/plasma/serum or saliva IgA [53,54]. NS1 assays are easy to use but limited in sensitivity, especially in secondary infections (common in endemic regions) [23,54], storage temperature, and cost [3,53]. IgG assays are limited in their inability to discriminate between recent and remote infection, and cannot detect early infection. Saliva IgA assays, alone, lack sensitivity during early primary DENV

infection [23]. Because of these limitations, many LMIC sites with known endemic DENV are using clinical features, such as bleeding, leukopenia, or thrombocytopenia, and contextual epidemiological information to diagnose DENV at this time. Lack of precise diagnostic testing for DENV can lead to confusion in areas where malaria and yellow fever, which can include a similar presentation, are endemic, and can also serve as a barrier to regional participation in clinical trials, which currently represent the only potential mechanism of direct antiviral therapy, and further development and distribution of rapid diagnostic tests, coupled with test standardization, is in progress [53]. Recent clinical trials have included virologic (RT-PCR for DENV viral load and tests for secreted DENV NS-1 antigen) and immunologic measurements (multiple cytokine measurements). Because RT-PCR and cytokine assay technology may not be readily available at many dengue endemic sites, distribution of clinical trial efforts may be skewed. However, there is the possibility that increased DENV-drug design efforts will bring with them the benefit of technology transfer providing additional LMIC sites with these helpful resources.

Treatment

While current treatment for DENV is supportive care, there are multiple anti-DENV agents in various stages of development.

Agents in Development for Anti-Dengue Activity

Direct acting antivirals

RNA dependent RNA polymerase (NS5) inhibitors: N-sulfonylanthranilic acid derivatives were identified as DENV RdRp inhibitors through screening of one million compounds using a primer extension RdRp assay [1]. The identified hit was found to bind DENV NS5 at the site of entrance to the RNA tunnel. While this specific compound is not under further development, the concept of inhibiting polymerase through the tunnel as well as other allosteric pockets is being pursued.

Nucleoside Analogues: Balapiravir (RG1626) is a prodrug of a nucleoside (cytidine) analog, R1479, which itself must be triphosphorylated for conversion into active form. Balapiravir was initially developed for the treatment of HCV, but clinical trials were stopped due to toxicity during extended treatment courses (2-3 months) in combination with pegylated interferon and ribavirin [55-57]. Because R1479 displayed *in vitro* anti dengue activity, and because of the shorter projected treatment duration for acute dengue infection (limiting toxicity), anti-dengue effects of balapiravir were explored in a phase II clinical trial [58]. An exploratory, dose-escalating, randomized placebo-controlled trial was conducted in adult male patients in Vietnam with dengue and <48 hours of fever. 32 subjects received five days of oral balapiravir (1500 or 3000 mg) for five days, and the medication was well tolerated. However, DENV viral loads, NS1 antigenemia, and fever clearance time were unaffected by treatment

[58]. The authors accurately state that “although this trial, the first of its kind in dengue, does not support balapiravir as a candidate drug, it does establish a framework for antiviral treatment trials in dengue and provides the field with a clinically evaluated benchmark molecule” Subsequent analyses determined that when human PBMCs were pre-infected with dengue (prior to balapiravir treatment), their ability to convert the prodrug balapiravir to the active, tri-phosphorylated nucleoside analog, R1479, form, was significantly impaired, resulting in decreased potency [59]. These *in vitro* studies also found that activation of NITD008, an adenosine based nucleoside analog [60], was less affected by dengue pre-infection, opening the possibility that further exploration of NITD008 may be warranted. A related compound, NITD203, was found to exhibit potent *in vitro* and *in vivo* anti-DENV efficacy, but satisfactory no-observable-adverse-effect levels could not be reached in 2 week *in vivo* toxicity studies [61].

Protease (NS2b-NS3) inhibitors: Recombinant retrocyclin 1. Rothan et al produced recombinant NS2B-NS3 protease in *E. coli* and identified recombinant retrocyclin 1, a cationic cyclic peptide theta defensin analogue with anti-HIV activity [62], as a potent DENV protease inhibitor [48].

BP13944: A screen of 60,000 chemical compounds in a DENV serotype 2 luciferase harboring replicon (BHK-21 cells) have recently identified BP13944, a quaternary ammonium salt, as an NS3 protease inhibitor [63].

α -ketoamides: Steuer et al designed an electrophilic trap for the serine component of the DENV NS2b-NS3 serine protease, and have identified α -ketoamides as DENV protease inhibitors [64].

Quinoline containing compounds: Using virtual screening for DENV protease inhibitors followed by scaffold hopping, to expand chemical diversity, then a DENV luciferase reporter replicon assay, Deng et al have described 17 new compounds with NS2b-NS3 protease inhibitor activity, which can now serve as potential lead structures for further discovery efforts [65].

NS4b inhibitor. Van Cleef et al recently screened the NIH Clinical Collection of drug-like small molecules for anti-DENV activity in HeLa cells harboring a subgenomic DENV2-replicon reporter and identified the δ opioid receptor antagonist SDM25N as potent DENV inhibitor [66].

Methyltransferase (NS5) inhibitors: Using a fragment-based drug discovery approach, Coutard et al recently screened 500 drug-like fragments by thermal-sift assay for binding to the DENV NS3 helicase or NS5 methyltransferase, and identified 7 validated MTase binders, each containing 5-6 membered aromatic rings [67].

Translation inhibitors. Wang et al performed a high throughput screen for reduction or elimination of DENV CPE and identified benzomorphan compounds that inhibit DENV through suppression of RNA translation and also inhibit DENV viremia in mice, though higher doses were limited by toxicity [68].

Capsid inhibitor: A high throughput small molecule screen with readout of DENV induced CPE was performed on over 200,000 compounds and identified ST-148 as a unique inhibitor of the DENV capsid protein with both *in vitro* and *in vivo* effects (AG129 mice) [69].

Peptide Inhibitors of Various DENV proteins: Several groups have recently proposed the use of peptide inhibitors to block DENV infection [70-76]. For example, Lok et al have identified the mimetic peptide DN59, which corresponds to a region of the dengue virus

envelope protein, as an inhibitor of all four serotypes of dengue virus [70]. They have found that DN59 incubation with DENV virus particles leads to viral membrane disruption and release of DENV RNA from the viral particles, but was non-toxic to mammalian cells [70]. In another study, 2 synthetic antiviral peptides were designed against target domain III of DENV2 envelope protein, and were found to exhibit significant DENV inhibition *in vitro* [73]. Prusis et al designed 45 peptide inhibitors against the DENV NS2b-NS3 protease and identified the tetrapeptide WCW-NH2 as an inhibitor of DENV 1-4 proteases [74].

Host Modulators

The compact 11 kb genome of DENV forces DENV to rely on multiple host factors for replication. This property can be exploited in attempts to inhibit viral replication through deprivation of these required host factors, or dependency factors. This strategy, targeting host factors to impede dengue viral infection, has recently been reviewed [30].

Ribavirin

Ribavirin is a broad acting inhibitor of RNA and DNA viruses. It is a synthetic guanosine analog which inhibits inosine monophosphate dehydrogenase with resulting GTP pool depletion [77], but has multiple additional proposed mechanisms of action, including up regulation of antiviral genes [78,79]. Ribavirin use has been limited by toxicity of both aerosolized and oral formulations, decreasing its clinical efficacy [80]. The complete compendium of downstream effectors of ribavirin antiviral effects is unknown. Ribavirin has been shown to have anti-DENV properties in several cell lines and primary cells [81,82], and is often used as a positive control in cell culture assays for anti-DENV compounds. However, ribavirin was not demonstrated to have anti-DENV activity in either a mouse (AG129) or a primate model of DENV viremia [83,84]. However, more recent studies have described potentiation of sub-effective dose alpha glucosidase inhibitor CM-10-18 by ribavirin in AG129 mice, underscoring a possible role for ribavirin as a treatment enhancer, similar to its role in peg-IFN treatment of HCV [85].

Mycophenolic Acid

The immunosuppressive agent mycophenolic acid (MPA), a nonnucleoside inhibitor of IMP dehydrogenase, has also been shown to inhibit dengue in cell culture, reproduced in four hepatoma cell lines, by preventing synthesis and accumulation of viral RNA [86].

Agents that Target Host Mediated Post Translational Modifications

α Glucosidase inhibitors

Flavivirus assembly occurs at the host endoplasmic reticulum where DENV structural proteins prM and E colocalize to form an immature particle in the ER lumen, where a high mannose carbohydrate, (Glc)3(Man)9(GlcNAc)2, is added in the ER to specific asparagine residues on the prM and E proteins [87,88]. This carbohydrate is then modified by host α -glucosidases to generate N-linked glycans that lack the terminal α (1,2) and α (1,3) glucose residues [89]. It has been found that trimming these N-linked carbohydrates in the ER may be required for DENV assembly or secretion of DEN [88,90,91]. α glucosidase inhibitors include the naturally occurring iminosugar castanospermine and also deoxynojirimycin, isolated from *Bacillus*. Castanospermine was found to inhibit infection with all four DENV serotypes *in vitro*,

and also to prevent dengue mortality in an A/J DENV mouse model [88]. More recently, a pro-drug of castanospermine, 6-O-butanoyl castanospermine, or celgosivir, has found to fully protect AG129 mice from lethal infection with mouse adapted DENV when given up to 48h following infection, and pharmacokinetic studies showed that celgosivir is rapidly metabolized to castanospermine in mice [92,93]. A randomized, double-blind, placebo-controlled, phase 1b clinical study to evaluate the activity, pharmacokinetics, safety and tolerability of celgosivir was conducted in adults with confirmed dengue fever in Singapore between 2012 and 2013 (ClinicalTrials.gov identifier NCT01619969). Results of that trial are anxiously awaited.

In parallel, another group examined the anti-DENV effects of the iminosugar drug UV-4, derived from deoxynojirimycin, *in vivo* in the AG129 mouse model, and found that UV-4 reduced mortality, DENV viremia, tissue levels of viral RNA, and virus induced cytokines, and that UV-4 also decreased mortality in an ADE model of secondary DENV infection [94]. Importantly, UV-4 treatment could be delayed up to 48 h in this mouse model, indicating its potential role as a therapeutic, though the therapeutic window is narrow because if administered at 72 h post infection, antiviral effects were no longer present [94]. In an outbreak setting, such early or possibly pre-emptive treatment could still be both feasible and useful. A phase I study of UV-4 opened in February 2014 (NCT02061358).

Other alpha glucosidase inhibitors, including N-alkyldeoxynojirimycin derivatives [95] and α glucosidase substrate mimics, such as CM 9 78 and CM 10 18, are in development [85,96]. Perhaps one of the most exciting recent developments in the field, a recent study of co administration of the α glucosidase inhibitor CM-1018 with ribavirin led to significant reduction of viremia in mice [85], for the first time providing data that the *in vitro* anti-DENV effects of ribavirin can be unlocked *in vivo* in the appropriate setting.

Cyclosporine blocks DENV NS5 interaction with the host dependency factor, cyclophilin, leading to DENV inhibition [97].

Lovastatin

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, used for lipid lowering and mortality reduction in cardiovascular disease, and have an excellent safety profile [98,99]. Statins have been found to exhibit anti-DENV properties in both cell culture and mouse models [100-102]. A clinical trial examining the safety and antiviral properties of lovastatin in adult patients is now ongoing in Vietnam [103].

Heparin and Heparan Sulfate

It is interesting to note that highly sulfated heparan sulfate is involved in initial interactions between the DENV E glycoprotein and the host cell, and heparin and heparan sulfate like molecules have been found to have anti-DENV properties [104-111]. The important complexities of DENV infection and host coagulation state will not be explored in this review.

Vitamin D

Treatment of both monocytic (U937) and hepatic (Huh 7) cells with 1 α , 25-dihydroxy-vitamin D3 was associated with decreased levels of DENV infection [112].

Host Kinase Inhibitors

Using an immunofluorescence imagebased assay suitable for identification of small molecule inhibitors of dengue virus infection

and replication, Chu et al identified AZD0530 and dasatinib, inhibitors of Src and Abl kinases, as potent DENV inhibitors. More recently, this group has determined that AZD0530 and dasatinib inhibit DENV viral RNA replication through inhibition of the host dependency factor, Fyn kinase [113]. Of note, AZD0530 (saracatinib) is in advanced clinical trials, pending FDA approval, while dasatinib is FDA approved.

Viral sensor (RIG-I and TLR3) agonists

The innate immune system includes detection of viral RNA by the helicase domain of RIG-I [114,115]. A synthetic 5' triphosphate (5'ppp) RNA was designed to stimulate this host innate immune response as an antiviral therapeutic, and was found to have anti DENV effects when transfected into A549 cells as well as primary human monocytes prior to DENV infection [116]. Along a similar vein, Diwaker et al have recently identified the RIG-I inducer Rhodiola as an inhibitor of DENV in human peripheral blood mononuclear cells and the human monocytic cell THP1 cell line, when administered 2 hours after DENV infection [117]. Et al showed that TLR3 activation through administration of the dsRNA compound PIKA prior to DENV infection decreased DENV infection of HepG2 cells [118].


Interferon

The type 1 IFNs, including IFN α , are among the broadest acting antiviral therapeutics known [119]. IFN α is a current component of anti-HCV therapy and has also been used with success for hepatitis B, severe acute respiratory syndrome, and WNV ([120-122]). Severe viral infection is often the result of subversion of the host immune response, rendering that response ineffective. A major common pathway of viral immune escape is suppression of the IFN α pathway (Figure 2) [33,123-143]. While IFN escape mechanisms vary from virus to virus, activation of IFN effectors downstream of viral subversion may identify common drug targets for restoration of an effective host antiviral response [30,144,145] (Figure 2). Although it will likely soon be possible to reduce reliance on IFN α in HCV treatment regimens [146-149], understanding the mechanism of this broad-acting antiviral will inform design of agents active against many viruses, such as DENV, that antagonize IFN α and for which no current treatment is available [124,126,132,134-137,150]. Elucidating the antiviral mechanism(s) of IFN α will also improve understanding of host-virus interactions, including variable human susceptibility to viruses and response to IFN or potential IFN-related therapies.

IFN Activation will Circumvent Viral Subversion of IFN Signaling

Type I IFN (α and/or β) binds to the type 1 IFN receptor (IFNAR1/2), which interacts with JAK1/TYK2, which can be followed by activation of STAT1 and 2 and subsequent formation of the heterotrimeric complex IFN-stimulated gene factor 3, or ISGF3 (consisting of STAT1, STAT2, IRF9) (Figure 2) [123,144]. ISGF3 then translocates to the nucleus, and directs transcription of hundreds of IFN stimulated genes (ISGs) through an IFN stimulated response element (ISRE) [123]. When intact, this system is highly effective in limiting viral infection. However, many pathogenic viruses have evolved mechanisms to escape the type I IFN response [33,132,134-136,150,151]. For example, HCV inactivates a host protein required for endogenous IFN production (mitochondrial antiviral signaling protein (MAVS), also known as IPS-1 and VISA) [152,153]. Downstream of IFN production, HCV also inhibits the activity of IFN (endogenous or exogenous) [154].

In general, IFN α can successfully inhibit DENV if given pre-infection, but not post-infection, due to DENV mediated suppression



of early members of the IFN signaling pathway [140,155], though some antiviral effect was observed in post-infection administration of PEG-rIFN- α -2a, which significantly lowered daily viremia levels and improved virus clearance, in rhesus monkeys [156]. Defining where viruses block, or subvert, the host IFN response can inform design of antivirals that act downstream of that block. In preliminary studies, we have identified 120 host antiviral candidates in a whole genome siRNA screen for HCV IEGs [44]. In addition, we have screened these 120 HCV IEG knockdowns for rescue of DENV from IFN in HeLa cells and have identified a subset of 45 HCV/DENV IEGs. Among our 45 HCV/DENV IEGs, we detected 6 known ISGs, including JAK1 and STAT2. While JAK1 and STAT2 lie proximal to likely subversion by Flaviviridae (Figure 2), the remaining 4 DENV/HCV IEG/ISGs are likely downstream of this block, and may serve as candidates for IEG activation. Broad-acting IEG activation fits with criteria for identifying high-value targets for therapeutic intervention by (1) overcoming viral ability to inhibit IFN action or (2) acting downstream of the virus-mediated IFN block. Because of their downstream location, such therapeutics could have fewer systemic effects than IFN itself, which would contribute to improved tolerability and therapeutic index. As host rather than virally targeted agents, these therapeutics are predicted to have a high barrier to viral resistance.

D4 dopamine receptor antagonists

Smith et al have identified a class of tricyclic small molecule compounds, the dihydrobenzothiepinines (DHBTs), in a high throughput small molecule screen for DENV-2 inhibitors, using high content immunofluorescent assay readout in HEK293T cells [157,158]. They further determined that SKI-417616, a highly active DHBT, inhibited all 4 DENV serotypes *in vitro* at an early event in the DENV lifecycle, and identified the mechanism of activity as host D4 dopamine receptor

inhibition. The authors suggest that, *in vivo*, macrophage-expressed dopamine receptors may be targetable DENV dependency factors.

Ivermectin

The anti-helminthic drug ivermectin has been identified as an inhibitor of the nuclear importer importin α/β . Because DENV NS5 polymerase activity requires importin α/β , anti-viral properties of ivermectin were explored, and revealed that pre-treatment with ivermectin inhibited DENV infection of Vero cells [159]. Supporting NS5 inhibitor effects of ivermectin, Tay et al. have found that ivermectin pretreatment strongly inhibits the nuclear localization of NS5 during DENV 1, 2 infection of BHK-21 or Huh-7 cells, along with inhibition of DENV infection levels [160]. At the same time, Mastrangelo et al identified ivermectin as a DENV NS3 helicase inhibitor using an *in vitro* modelled helicase inhibition assay, and further confirmed ivermectin anti-DENV activity, though only for virus yield reduction (qRT-PCR) and less so for CPE reduction [161].

Pentoxifylline

A small clinical trial of the TNF α inhibitor, pentoxifylline, showed a potential decrease in mean length of ICU stay and decreased TNF α levels, though viral parameters were not assessed [162].

Chloroquine

Chloroquine is an inexpensive, widely available, well-tolerated lysosomotropic 4-amino-quinoline derivative, which is well known as an anti-malarial drug but also possesses *in vitro* anti-viral activity, including anti-DENV activity, potentially related to its effect of increasing endosomal pH [163,164]. *In vitro*, treatment with chloroquine caused a dose-dependent reduction of DV-1 infectivity in THP/DC-SIGN cells [165]. A clinical trial of anti-DENV efficacy of chloroquine was performed in Vietnam, where 154 adult patients with suspected dengue received 3d chloroquine versus placebo. While a trend toward lower incidence of dengue hemorrhagic fever was detected, chloroquine did not reduce the duration of DENV viremia or NS1 antigenemia [166].

Amodiaquine

The quinoline derivative amodiaquine was recently identified in a replicon based screen for anti-DENV agents, and confirmed to have anti-DENV activity in DENV2 plaque assays and qRT PCR assaying for both intracellular and extracellular DENV levels [46].

RNAi

RNA interference, or RNAi, is a gene silencing process which degrades target RNA in a sequence specific fashion. RNAi has been proposed as a strategy to directly inhibit viral infections, including DENV [167-170]. One group showed that use of dendritic cell-targeting peptide mediated delivery of siRNA against a conserved sequence in the DENV envelope effectively suppressed DENV replication in macrophages and monocytes [171]. In addition to RNAi-mediated suppression of DENV itself, RNAi-mediated suppression of viral dependency factors, or factor required by the virus for productive infection, has been shown to inhibit DENV [172,173]. There are currently no RNAi agents registered under clinicaltrials.gov when searched with dengue.

Interestingly, it has recently been found that the DENV NS4B protein of all four DENV serotypes acts as a suppressor of human intracellular RNAi machinery, including Dicer, Drosha, Ago1, and

Ago2, as well as many human microRNAs [174].

Morpholinos

Taking advantage of the RNA-RNA or RNA-protein interactions required for DENV replication, antisense peptide-conjugated phosphorodiamidate morpholino oligomers (P-PMOs) have been designed to sterically interfere with these interactions [175-178]. Holden et al. evaluated the mechanism and effectiveness of DEN 5' stem loop, DEN 3' cyclization sequence, and one more novel morpholino complementary to the top of the DENV 3' stem loop. They found that the 5'SL P-PMO blocked DENV viral translation, the 3'CX P-PMO blocked viral RNA synthesis, and the novel 3' SLT P-PMO blocked both viral translation and RNA synthesis, and could potentially be useful as therapeutics in human infection.

Other Compounds

Other agents that have been suggested to display anti-dengue activity include geneticin, an aminoglycoside antibiotic, which has been found to have the unique property, among aminoglycosides, of inhibiting DENV [179] and FCI 106, a compound of unknown mechanism identified in a screen for anti-Ebola agents, which has also been found to have anti-DENV activity, in DC-SIGN cells [180].

Medicinal plant derivatives

There is a significant amount of research dedicated to hypothesis-driven and practice-based identification of naturally occurring compounds with anti-dengue properties. While this literature will not be reviewed extensively here, several recent references are indicated [181-187]. It is important to note that many of the compounds examined in these studies are selected because they are already in use against dengue in traditional settings, underscoring the need to examine their effect on dengue-related outcomes, regardless of whether they will be assessed for drug development.

Summary

In summary, dengue virus has emerged as an increasingly worrisome arboviral disease, with 2.5 billion people currently living in regions at risk of disease, and innumerable others exposed through travel, with no realistic optimism of near-term vaccine or vector control, and incomplete understanding of factors predicting who will succumb to fatal infection. There are multiple leads for antiviral design advancing through the therapeutic development pipeline, and clinical trials are beginning. Major challenges ahead will include identification of compounds that validate *in vivo* [68], exhibit a highly favorable safety profile, are active beyond the earliest hours of infection, are inexpensive, and unlikely to be overcome by viral resistance. There is a significant amount of work to be done.

References

1. Niyomrattanakit P, Chen YL, Dong H, Yin Z, Qing M, et al. (2010) Inhibition of dengue virus polymerase by blocking of the RNA tunnel. *J Virol* 84: 5678-5686.
2. Yacoub S, Wertheim H, Simmons CP, Screaton G, Wills B (2014) Cardiovascular manifestations of the emerging dengue pandemic. *Nat Rev Cardiol* 11: 335-345.
3. Mayxay M, Castonguay-Vanier J, Chansamouth V2, Dubot-Peres A, Paris DH4, et al. (2013) Causes of non-malarial fever in Laos: a prospective study. *Lancet Glob Health* 1: e46-46e54.
4. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, et al. (2010) Dengue: a continuing global threat. *Nat Rev Microbiol* 8: S7-16.
5. Julander JG, Perry ST, Shrestha S (2011) Important advances in the field of anti-dengue virus research. *Antivir Chem Chemother* 21: 105-116.
6. Kularatne SA, Imbulpitaya IV, Abeysekera RA, Waduge RN, Rajapakse RP, et al. (2014) Extensive haemorrhagic necrosis of liver is an unpredictable fatal complication in dengue infection: a postmortem study. *BMC Infect Dis* 14: 141.
7. Sharp TM, Gaul L, Muehlenbachs A, Hunsperger E, Bhatnagar J, et al. (2014) Fatal hemophagocytic lymphohistiocytosis associated with locally acquired dengue virus infection - New Mexico and Texas, 2012. *MMWR Morb Mortal Wkly Rep* 63: 49-54.
8. Luk FO, Chan CK, Lai TY (2013) A case of dengue maculopathy with spontaneous recovery. *Case Rep Ophthalmol* 4: 28-33.
9. Sargeant T, Harris T, Wilks R, Bamed S, Galloway-Blake K, et al. (2013) Rhabdomyolysis and dengue Fever: a case report and literature review. *Case Rep Med* 2013: 101058.
10. Joshi R, Phatarpekar A, Currimbhoy Z, Desai M (2011) Haemophagocytic lymphohistiocytosis: a case series from Mumbai. *Ann Trop Paediatr* 31: 135-140.
11. Puccioni-Sohler M, Orsini M, Soares CN (2012) Dengue: a new challenge for neurology. *Neurol Int* 4: e15.
12. Ramachandran B, Balasubramanian S, Abhishek N, Ravikumar KG, Ramanan AV (2011) Profile of hemophagocytic lymphohistiocytosis in children in a tertiary care hospital in India. *Indian Pediatr* 48: 31-35.
13. Larik A, Chiong Y, Lee LC, Ng YS (2012) Longitudinally extensive transverse myelitis associated with dengue fever. *BMJ Case Rep* 2012.
14. Bowman S, Salgado C, DeWaay DJ (2012) Dengue fever presenting with hepatitis. *Am J Med Sci* 344: 335-336.
15. <http://www.cdc.gov/dengue/>
16. Linares EM, Pannuti CS, Kubota LT, Thalhammer S (2013) Immunospot assay based on fluorescent nanoparticles for Dengue fever detection. *Biosens Bioelectron* 41: 180-185.
17. San Martín JL, Brathwaite O, Zambrano B, Solórzano JO, Bouckennooghe A, et al. (2010) The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. *Am J Trop Med Hyg* 82: 128-135.
18. Chappuis F, Alriol E, d'Acremont V, Bottieau E, Yansouni CP (2013) Rapid diagnostic tests for non-malarial febrile illness in the tropics. *Clin Microbiol Infect* 19: 422-431.
19. Stoler J, Al Dashti R2, Anto F3, Fobil JN4, Awandare GA5 (2014) Deconstructing "malaria": West Africa as the next front for dengue fever surveillance and control. *Acta Trop* 134C: 58-65.
20. Añez G, Rios M (2013) Dengue in the United States of America: a worsening scenario? *Biomed Res Int* 2013: 678645.
21. Stahl HC, Butenschoen VM, Tran HT, Gozzer E, Skewes R, et al. (2013) Cost of dengue outbreaks: literature review and country case studies. *BMC Public Health* 13: 1048.
22. Mahalingam S, Herring BL, Halstead SB (2013) Call to action for dengue vaccine failure. *Emerg Infect Dis* 19: 1335-1337.
23. Yap G, Sil BK, Ng LC (2011) Use of saliva for early dengue diagnosis. *PLoS Negl Trop Dis* 5: e1046.
24. De Clercq E (2010) Strategies for the treatment of dengue virus infections: a narrative account. *Future Med Chem* 2: 601-608.
25. Pongpair O, Bangphoomi K2, Chaowalit P, Sawasdee N, Saokaew N3, et al. (2014) Generation of human single-chain variable fragment antibodies specific to dengue virus non-structural protein 1 that interfere with the virus infectious cycle. *MAbs* 6: 474-482.
26. Tam DT, Ngoc TV, Tien NT, Kieu NT, Thuy TT et al. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. *Clin Infect Dis* 2012. 55: 1216-1224.
27. Kurukularatne C, Dimatatac F, Teo DL, Lye DC, Leo YS (2011) When less is more: can we abandon prophylactic platelet transfusion in Dengue fever? *Ann Acad Med Singapore* 40: 539-545.
28. Khan Assir MZ, Kamran U, Ahmad HI, Bashir S, Mansoor H, et al. (2013) Effectiveness of platelet transfusion in dengue Fever: a randomized controlled trial. *Transfus Med Hemother* 40: 362-368.

29. Thomas SJ (2014) Developing a dengue vaccine: progress and future challenges. *Ann N Y Acad Sci*.
30. Krishnan MN, Garcia-Blanco MA2 (2014) Targeting host factors to treat West Nile and dengue viral infections. *Viruses* 6: 683-708.
31. Pastorino B, Nougairède A, Wurtz N, Gould E, de Lamballerie X (2010) Role of host cell factors in flavivirus infection: Implications for pathogenesis and development of antiviral drugs. *Antiviral Res* 87: 281-294.
32. Sayce AC, Miller JL, Zitzmann N (2010) Targeting a host process as an antiviral approach against dengue virus. *Trends Microbiol* 18: 323-330.
33. Muñoz-Jordan JL, Sánchez-Burgos GG, Laurent-Rolle M, García-Sastre A (2003) Inhibition of interferon signaling by dengue virus. *Proc Natl Acad Sci U S A* 100: 14333-14338.
34. Wilder-Smith A, Chen LH, Massad E, Wilson ME (2009) Threat of dengue to blood safety in dengue-endemic countries. *Emerg Infect Dis* 15: 8-11.
35. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzler PS, et al. (2009) Emerging infectious disease agents and their potential threat to transfusion safety. *Transfusion* 49 Suppl 2: 1S-29S.
36. Teo D, Ng LC, Lam S (2009) Is dengue a threat to the blood supply? *Transfus Med* 19: 66-77.
37. Wiwanitkit V (2009) Unusual mode of transmission of dengue. *J Infect Dev Ctries* 4: 51-54.
38. Mathew A, Rothman AL (2008) Understanding the contribution of cellular immunity to dengue disease pathogenesis. *Immunol Rev* 225: 300-313.
39. Wong KL, Chen W, Balakrishnan T, Toh YX, Fink K, et al. (2012) Susceptibility and response of human blood monocyte subsets to primary dengue virus infection. *PLoS One* 7: e36435.
40. Anna PD, José MV, Wanionek K, Samantha NH, Gordon A et al. (2008) Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. *Virology* 376: 429-35.
41. Warke RV, Becerra A, Zawadzka A, Schmidt DJ, Martin KJ et al. (2008) Efficient dengue virus (DENV) infection of human muscle satellite cells upregulates type I interferon response genes and differentially modulates MHC I expression on bystander and DENV-infected cells. *J Gen Virol* 89: 1605-1615.
42. Lee E, Weir RC, Dalgarno L (1997) Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein. *Virology* 232: 281-290.
43. Diamond MS, Edgil D, Roberts TG, Lu B, Harris E (2000) Infection of human cells by dengue virus is modulated by different cell types and viral strains. *J Virol* 74: 7814-7823.
44. Fusco DN, Brisac C, John SP, Huang YW, Chin CR, et al. (2013) A genetic screen identifies interferon- λ effector genes required to suppress hepatitis C virus replication. *Gastroenterology* 144: 1438-1449, 1449.
45. Massé N, Davidson A, Ferron F, Alvarez K, Jacobs M et al. (2010) Dengue virus replicons: production of an interserotypic chimera and cell lines from different species, and establishment of a cell-based fluorescent assay to screen inhibitors, validated by the evaluation of ribavirin's activity. *Antiviral Res* 86: 296-305.
46. Boonyasuppayakorn S, Reichert ED2, Manzano M3, Nagarajan K4, Padmanabhan R5 (2014) Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity. *Antiviral Res* 106: 125-134.
47. Rothan HA, Abdulrahman AY, Sasikumer PG, Othman S, Rahman NA, et al. (2012) Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral replication in MK2 cells. *J Biomed Biotechnol* 2012: 251482.
48. Rothan HA, Han HC, Ramasamy TS, Othman S, Rahman NA, et al. (2012) Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1. *BMC Infect Dis* 12: 314.
49. Bhattacharyya A, Trotta CR, Peltz SW (2007) Mining the GEMS--a novel platform technology targeting post-transcriptional control mechanisms. *Drug Discov Today* 12: 553-560.
50. Frias-Staheli N, Dörner M, Marukian S, Billerbeck E, Labitt RN, et al. (2014) Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing. *J Virol* 88: 2205-2218.
51. Watanabe S, Vasudevan SG (2014) Evaluation of dengue antiviral candidates *in vivo* in mouse model. *Methods Mol Biol* 1138: 391-400.
52. Zompi S, Harris E (2012) Animal models of dengue virus infection. *Viruses* 4: 62-82.
53. Blacksell SD (2012) Commercial dengue rapid diagnostic tests for point-of-care application: recent evaluations and future needs? *J Biomed Biotechnol* 2012: 151967.
54. Tan YY, Sekaran SD, Wang SM, Ahmed F, Hossain A, et al. (2011) Development of ASSURE Dengue IgA Rapid Test for the Detection of Anti-dengue IgA from Dengue Infected Patients. *J Glob Infect Dis* 3: 233-240.
55. Brandl M, Wu X, Holper M, Hong L, Jia Z, et al. (2008) Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability. *Drug Dev Ind Pharm* 34: 683-691.
56. Klumpp K, Lévêque V, Le Pogam S, Ma H, Jiang WR, et al. (2006) The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. *J Biol Chem* 281: 3793-3799.
57. Roberts SK, Cooksley G, Dore GJ, Robson R, Shaw D, et al. (2008) Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. *Hepatology* 48: 398-406.
58. Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh Hle A, et al. (2013) A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. *J Infect Dis* 207: 1442-1450.
59. Chen YL, Abdul Ghafar N, Karuna R, Fu Y, Lim SP, et al. (2014) Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir. *J Virol* 88: 1740-1747.
60. Yin Z, Chen YL, Schul W, Wang QY, Gu F, et al. (2009) An adenosine nucleoside inhibitor of dengue virus. *Proc Natl Acad Sci U S A* 106: 20435-20439.
61. Chen YL, Yin Z, Lakshminarayana SB, Qing M, Schul W, et al. (2010) Inhibition of dengue virus by an ester prodrug of an adenosine analog. *Antimicrob Agents Chemother* 54: 3255-3261.
62. Daly NL, Chen YK, Rosengren KJ, Marx UC, Phillips ML, et al. (2007) Retrocyclin-2: structural analysis of a potent anti-HIV theta-defensin. *Biochemistry* 46: 9920-9928.
63. Yang CC, Hu HS, Wu RH, Wu SH, Lee SJ, et al. (2014) A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease. *Antimicrob Agents Chemother* 58: 110-119.
64. Steuer C, Gege C, Fischl W, Heinonen KH, Bartenschlager R, et al. (2011) Synthesis and biological evaluation of alpha-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture. *Bioorg Med Chem* 19: 4067-4074.
65. Deng J, Li N, Liu H, Zuo Z, Liew OW, et al. (2012) Discovery of novel small molecule inhibitors of dengue viral NS2B-NS3 protease using virtual screening and scaffold hopping. *J Med Chem* 55: 6278-6293.
66. van Cleef KW, Overheul GJ, Thomassen MC, Kaptein SJ, Davidson AD, et al. (2013) Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication. *Antiviral Res* 99: 165-171.
67. Coutard B, Decroly E, Li C, Sharff A, Lescar J, et al. (2014) Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery. *Antiviral Res* 106: 61-70.
68. Wang QY, Kondreddi RR, Xie X, Rao R, Nilar S, et al. (2011) A translation inhibitor that suppresses dengue virus *in vitro* and *in vivo*. *Antimicrob Agents Chemother* 55: 4072-4080.
69. Byrd CM, Dai D, Grosenbach DW, Berhanu A, Jones KF, et al. (2013) A novel inhibitor of dengue virus replication that targets the capsid protein. *Antimicrob Agents Chemother* 57: 15-25.
70. Lok SM, Costin JM, Hrobowski YM, Hoffmann AR, Rowe DK, et al. (2012) Release of dengue virus genome induced by a peptide inhibitor. *PLoS One* 7: e50995.
71. Hrobowski YM, Garry RF, Michael SF (2005) Peptide inhibitors of dengue virus and West Nile virus infectivity. *Virol J* 2: 49.

72. Schmidt AG, Yang PL, Harrison SC (2010) Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate. *PLoS Pathog* 6: e1000851.
73. Alhoot MA, Rathinam AK, Wang SM, Manikam R, Sekaran SD (2013) Inhibition of dengue virus entry into target cells using synthetic antiviral peptides. *Int J Med Sci* 10: 719-729.
74. Prusis P, Junaid M, Petrovska R, Yahorava S, Yahorau A, et al. (2013) Design and evaluation of substrate-based octapeptide and non substrate-based tetrapeptide inhibitors of dengue virus NS2B-NS3 proteases. *Biochem Biophys Res Commun* 434: 767-772.
75. Panya A, Bangphoomi K, Choowongkamon K, Yenchitsomanus PT (2014) Peptide Inhibitors Against Dengue Virus Infection. *Chem Biol Drug Des* .
76. Parikesit AA, Kinanty, Tambunan US (2013) Screening of commercial cyclic peptides as inhibitor envelope protein dengue virus (DENV) through molecular docking and molecular dynamics. *Pak J Biol Sci* 16: 1836-1848.
77. Leyssen P, Balzarini J, De Clercq E, Neyts J (2005) The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. *J Virol* 79: 1943-1947.
78. Zhang Y, Jamaluddin M, Wang S, Tian B et al. (2003) Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. *J Virol* 77: 5933-5947.
79. Thomas E, Ghany MG, Liang TJ (2012) The application and mechanism of action of ribavirin in therapy of hepatitis C. *Antivir Chem Chemother* 23: 1-12.
80. Empey KM, Peebles RS Jr, Kolls JK (2010) Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. *Clin Infect Dis* 50: 1258-1267.
81. Takhampunya R, Ubol S, Houg HS, Cameron CE, Padmanabhan R (2006) Inhibition of dengue virus replication by mycophenolic acid and ribavirin. *J Gen Virol* 87: 1947-1952.
82. Huang YH, Lei HY, Liu HS, Lin YS, Liu CC, et al. (2000) Dengue virus infects human endothelial cells and induces IL-6 and IL-8 production. *Am J Trop Med Hyg* 63: 71-75.
83. Malinoski FJ, Hastly SE, Ussery MA, Dalrymple JM (1990) Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. *Antiviral Res* 13: 139-149.
84. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG (2007) A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. *J Infect Dis* 195: 665-674.
85. Chang J, Schul W, Butters TD, Yip A, Liu B, et al. (2011) Combination of β -glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. *Antiviral Res* 89: 26-34.
86. Diamond MS, Zachariah M, Harris E (2002) Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. *Virology* 304: 211-221.
87. Chambers TJ, Hahn CS, Galler R, Rice CM (1990) Flavivirus genome organization, expression, and replication. *Annu Rev Microbiol* 44: 649-688.
88. Whitby K, Pierson TC, Geiss B, Lane K, Engle M, et al. (2005) Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. *J Virol* 79: 8698-8706.
89. Hebert DN, Foellmer B, Helenius A (1996) Calnexin and calreticulin promote folding, delay oligomerization and suppress degradation of influenza hemagglutinin in microsomes. *EMBO J* 15: 2961-2968.
90. Courageot MP, Frenkiel MP, Dos Santos CD, Deubel V, Desprès P (2000) Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. *J Virol* 74: 564-572.
91. Wu SF, Lee CJ, Liao CL, Dwek RA, Zitzmann N, et al. (2002) Antiviral effects of an iminosugar derivative on flavivirus infections. *J Virol* 76: 3596-3604.
92. Watanabe S, Rathore AP, Sung C, Lu F, Khoo YM et al. (2012) Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. *Antiviral Res* 96: 32-35.
93. Rathore AP, Paradkar PN, Watanabe S, Tan KH, Sung C, et al. (2011) Celgosivir treatment misfolds dengue virus NS protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. *Antiviral Res* 92: 453-460.
94. Perry ST, Buck MD, Plummer EM, Penmasta RA, Batra H, et al. (2013) An iminosugar with potent inhibition of dengue virus infection in vivo. *Antiviral Res* 98: 35-43.
95. Du Y, Ye H, Gill T, Wang L, Guo F, et al. (2013) N-Alkyldeoxyojirimycin derivatives with novel terminal tertiary amide substitution for treatment of bovine viral diarrhea virus (BVDV), Dengue, and Tacaribe virus infections. *Bioorg Med Chem Lett* 23: 2172-2176.
96. Chang J, Schul W, Yip A, Xu X, Guo JT, et al. (2011) Competitive inhibitor of cellular β -glucosidases protects mice from lethal dengue virus infection. *Antiviral Res* 92: 369-371.
97. Qing M, Yang F, Zhang B, Zou G, Robida JM et al. (2009) Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein. *Antimicrob Agents Chemother*, 53: 3226-35.
98. Brookes ZL, McGown CC, Reilly CS (2009) Statins for all: the new premed? *Br J Anaesth* 103: 99-107.
99. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, et al. (2002) ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. *Stroke* 33: 2337-2341.
100. Martínez-Gutiérrez M, Castellanos JE, Gallego-Gómez JC (2011) Statins reduce dengue virus production via decreased virion assembly. *Intervirology* 54: 202-216.
101. Martínez-Gutiérrez M, Correa-Londoño LA2, Castellanos JE3, Gallego-Gómez JC4, Osorio JE5 (2014) Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. *PLoS One* 9: e87412.
102. Rothwell C, Lebreton A, Young Ng C, Lim JY, Liu W, et al. (2009) Cholesterol biosynthesis modulation regulates dengue viral replication. *Virology* 389: 8-19.
103. Whitehorn J, Van Vinh Chau N, Truong NT, Tai LT, Van Hao N, et al. (2012) Lovastatin for adult patients with dengue: protocol for a randomised controlled trial. *Trials* 13: 203.
104. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, et al. (1997) Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. *Nat Med* 3: 866-871.
105. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, et al. (2002) Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. *Virology* 292: 162-168.
106. Ono L, Wollinger W, Rocco IM, Coimbra TL, Gorin PA, et al. (2003) In vitro and in vivo antiviral properties of sulfated galactomannans against yellow fever virus (Beh11 strain) and dengue 1 virus (Hawaii strain). *Antiviral Res* 60: 201-208.
107. Talarico LB, Damonte EB (2007) Interference in dengue virus adsorption and uncoating by carrageenans. *Virology* 363: 473-485.
108. Talarico LB, Pujol CA, Zibetti RG, Faria PC, Nosedá MD, et al. (2005) The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. *Antiviral Res* 66: 103-110.
109. Talarico LB, Nosedá MD, Ducatti DR, Duarte ME, Damonte EB (2011) Differential inhibition of dengue virus infection in mammalian and mosquito cells by iota-carrageenan. *J Gen Virol* 92: 1332-1342.
110. Chen J, Yamada S, Hama Y, Shetty AK, Kobayashi T, et al. (2011) Unique heparan sulfate from shrimp heads exhibits a strong inhibitory effect on infections by dengue virus and Japanese encephalitis virus. *Biochem Biophys Res Commun* 412: 136-142.
111. Lin YL, Lei HY, Lin YS, Yeh TM, Chen SH, et al. (2002) Heparin inhibits dengue-2 virus infection of five human liver cell lines. *Antiviral Res* 56: 93-96.
112. Puerta-Guardo H, Medina F, De la Cruz Hernández SI, Rosales VH, Ludert JE, et al. (2012) The $1\beta,25$ -dihydroxy-vitamin D₃ reduces dengue virus infection in human myelomonocyte (U937) and hepatic (Huh-7) cell lines and cytokine production in the infected monocytes. *Antiviral Res* 94: 57-61.
113. de Wispelaere M, LaCroix AJ, Yang PL (2013) The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. *J Virol* 87: 7367-7381.

114. Jiang F, Ramanathan A, Miller MT, Tang GQ, Gale M Jr, et al. (2011) Structural basis of RNA recognition and activation by innate immune receptor RIG-I. *Nature* 479: 423-427.
115. Yoneyama M, Fujita T (2007) Function of RIG-I-like receptors in antiviral innate immunity. *J Biol Chem* 282: 15315-15318.
116. Goulet ML, Olanier D, Xu Z, Paz S, Belgnaoui SM, et al. (2013) Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. *PLoS Pathog* 9: e1003298.
117. Diwaker D, Mishra KP, Ganju L, Singh SB (2014) Rhodiola inhibits dengue virus multiplication by inducing innate immune response genes RIG-I, MDA5 and ISG in human monocytes. *Arch Virol* .
118. Zhang P, Wu S, Li L, Liang Z, Li Y, et al. (2013) Adjuvant PIKA protects hepatoma cells from dengue virus infection by promoting a TBK-1-dependent innate immune response. *Arch Virol* 158: 829-838.
119. ISAACS A, LINDENMANN J (1957) Virus interference. I. The interferon. *Proc R Soc Lond B Biol Sci* 147: 258-267.
120. Dusheiko G (2013) Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. *Liver Int* 33 Suppl 1: 137-150.
121. Mazzulli T, Kain K, Butany J (2004) Severe acute respiratory syndrome: overview with an emphasis on the Toronto experience. *Arch Pathol Lab Med* 128: 1346-1350.
122. Rahal JJ (2005) Methods of Treating West Nile Virus Infection, The New York Hospital Medical Center of Queens, Flushing, NY (US): US.
123. Wang BX, Fish EN (2012) The yin and yang of viruses and interferons. *Trends Immunol* 33: 190-197.
124. Dong C, Zafrullah M, Mixson-Hayden T, Dai X, Liang J, et al. (2012) Suppression of interferon- α signaling by hepatitis E virus. *Hepatology* 55: 1324-1332.
125. Bellecave P, Sarasin-Filipowicz M, Donz  O, Kennel A, Gouttenoire J, et al. (2010) Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. *Hepatology* 51: 1127-1136.
126. Mazzon M, Jones M, Davidson A, Chain B, Jacobs M (2009) Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. *J Infect Dis* 200: 1261-1270.
127. Feng X, Ratner L (2008) Human T-cell leukemia virus type 1 blunts signaling by interferon alpha. *Virology* 374: 210-216.
128. Lefort S, A Gravel, L Flamand (2010) Repression of interferon-alpha stimulated genes expression by Kaposi's sarcoma-associated herpesvirus K-bZIP protein. *Virology* 408: 14-30.
129. Meng X, Schoggins J, Rose L, Cao J, Ploss A, et al. (2012) C7L family of poxvirus host range genes inhibits antiviral activities induced by type I interferons and interferon regulatory factor 1. *J Virol* 86: 4538-4547.
130. Kubota T, Matsuoka M, Chang TH, Taylor P, Sasaki T, et al. (2008) Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. *J Biol Chem* 283: 25660-25670.
131. Scholle F, Mason PW (2005) West Nile virus replication interferes with both poly(I:C)-induced interferon gene transcription and response to interferon treatment. *Virology* 342: 77-87.
132. Liu WJ, Wang XJ, Mokhonov VV, Shi PY, Randall R, et al. (2005) Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. *J Virol* 79: 1934-1942.
133. Diamond MS, Gale M Jr (2012) Cell-intrinsic innate immune control of West Nile virus infection. *Trends Immunol* 33: 522-530.
134. Laurent-Rolle M, Boer EF, Lubick KJ, Wolfenbarger JB, Carmody AB, et al. (2010) The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. *J Virol* 84: 3503-3515.
135. Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, et al. (2005) Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. *J Virol* 79: 5414-5420.
136. Guo JT, Hayashi J, Seeger C (2005) West Nile virus inhibits the signal transduction pathway of alpha interferon. *J Virol* 79: 1343-1350.
137. Guo CJ, Yang LS, Zhang YF, Wu YY, Weng SP, et al. (2012) A novel viral SOCS from infectious spleen and kidney necrosis virus: interacts with Jak and inhibits IFN- α induced Stat1/3 activation. *PLoS One* 7: e41092.
138. Basler CF (2012) Nipah and hendra virus interactions with the innate immune system. *Curr Top Microbiol Immunol* 359: 123-152.
139. Oksayan S, Ito N, Moseley G, Blondel D (2012) Subcellular trafficking in rhabdovirus infection and immune evasion: a novel target for therapeutics. *Infect Disord Drug Targets* 12: 38-58.
140. Morrison J, Aguirre S, Fernandez-Sesma A (2012) Innate immunity evasion by Dengue virus. *Viruses* 4: 397-413.
141. Hughes R, Towers G, Noursadeghi M (2012) Innate immune interferon responses to human immunodeficiency virus-1 infection. *Rev Med Virol* 22: 257-266.
142. Thimme R, Binder M, Bartenschlager R (2012) Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. *FEMS Microbiol Rev* 36: 663-683.
143. Garc a-Sastre A (2011) Induction and evasion of type I interferon responses by influenza viruses. *Virus Res* 162: 12-18.
144. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. *Nature* 472: 481-485.
145. Liu SY, Sanchez DJ, Aliyari R, Lu S, Cheng G (2012) Systematic identification of type I and type II interferon-induced antiviral factors. *Proc Natl Acad Sci U S A* 109: 4239-4244.
146. Welsch C, Jesudian A, Zeuzem S, Jacobson I (2012) New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. *Gut* 61 Suppl 1: i36-46.
147. Fusco DN, Chung RT (2011) New protease inhibitors for HCV--help is on the way. *J Hepatol* 54: 1087-1089.
148. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, et al. (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med* 370: 1483-1493.
149. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, et al. (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med* 370: 1889-1898.
150. Mu oz-Jord n JL (2010) Subversion of interferon by dengue virus. *Curr Top Microbiol Immunol* 338: 35-44.
151. Mu oz-Jord n JL, Laurent-Rolle M, Ashour J, Mart nez-Sobrido L, Ashok M, et al. (2005) Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. *J Virol* 79: 8004-8013.
152. Arnaud N, Dabo S, Maillard P, Budkowska A, Kalliampakou KI, et al. (2010) Hepatitis C virus controls interferon production through PKR activation. *PLoS One* 5: e10575.
153. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, et al. (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. *Nature* 437: 1167-1172.
154. Garaigorta U, Chisari FV (2009) Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. *Cell Host Microbe* 6: 513-522.
155. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, et al. (2000) Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. *J Virol* 74: 4957-4966.
156. Ajariyakhajom C, Mammen MP, Endy TP, Gettayacamin M, Nisalak A et al. (2005) Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys. *Antimicrob Agents Chemother*. 49: 4508-4514.
157. Smith JL, Stein DA, Shum D, Fischer MA, Radu C, et al. (2014) Inhibition of dengue virus replication by a class of small-molecule compounds that antagonize dopamine receptor d4 and downstream mitogen-activated protein kinase signaling. *J Virol* 88: 5533-5542.

158. Shum D, Smith JL, Hirsch AJ, Bhinder B, Radu C, et al. (2010) High-content assay to identify inhibitors of dengue virus infection. *Assay Drug Dev Technol* 8: 553-570.
159. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA (2012) Ivermectin is a specific inhibitor of importin β -mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. *Biochem J* 443: 851-856.
160. Tay MY, Fraser JE, Chan WK, Moreland NJ, Rathore AP, et al. (2013) Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. *Antiviral Res* 99: 301-306.
161. Mastrangelo E, Pezzullo M, De Burghgraeve T, Kaptein S, Pastorino B, et al. (2012) Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. *J Antimicrob Chemother* 67: 1884-1894.
162. Salgado D, Zabaleta TE, Hatch S, Vega MR, Rodriguez J (2012) Use of pentoxifylline in treatment of children with dengue hemorrhagic fever. *Pediatr Infect Dis J* 31: 771-773.
163. Farias KJ, Machado PR, da Fonseca BA (2013) Chloroquine inhibits dengue virus type 2 replication in Vero cells but not in C6/36 cells. *ScientificWorldJournal* 2013: 282734.
164. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (2003) Effects of chloroquine on viral infections: an old drug against today's diseases? *Lancet Infect Dis* 3: 722-727.
165. Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz O, Fieschi F, et al. (2003) Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. *EMBO Rep* 4: 723-728.
166. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, et al. (2010) A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. *PLoS Negl Trop Dis* 4: e785.
167. Idrees S, Ashfaq UA, Khaliq S (2013) RNAi: antiviral therapy against dengue virus. *Asian Pac J Trop Biomed* 3: 232-236.
168. Zhang W, Singam R, Hellermann G, Kong X, Juan HS, et al. (2004) Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery. *Genet Vaccines Ther* 2: 8.
169. Stein DA, Perry ST, Buck MD, Oehmen CS, Fischer MA, et al. (2011) Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence. *J Virol* 85: 10154-10166.
170. Korrapati AB, Swaminathan G, Singh A, Khanna N, Swaminathan S (2012) Adenovirus delivered short hairpin RNA targeting a conserved site in the 5' non-translated region inhibits all four serotypes of dengue viruses. *PLoS Negl Trop Dis* 6: e1735.
171. Subramanya S, Kim SS, Abraham S, Yao J, Kumar M, et al. (2010) Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. *J Virol* 84: 2490-2501.
172. Alhoot MA, Wang SM, Sekaran SD (2012) RNA interference mediated inhibition of dengue virus multiplication and entry in HepG2 cells. *PLoS One* 7: e34060.
173. Padwad YS, Mishra KP, Jain M, Chanda S, Karan D et al. (2009) RNA interference mediated silencing of Hsp60 gene in human monocytic myeloma cell line U937 revealed decreased dengue virus multiplication. *Immunobiology* 214: 422-429.
174. Kakumani PK, Ponia SS, S RK, Sood V, Chinnappan M, et al. (2013) Role of RNA interference (RNAi) in dengue virus replication and identification of NS4B as an RNAi suppressor. *J Virol* 87: 8870-8883.
175. Kinney RM, Huang CY, Rose BC, Kroeker AD, Dreher TW, et al. (2005) Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers. *J Virol* 79: 5116-5128.
176. Stein DA, Huang CY, Silengo S, Amantana A, Crumley S, et al. (2008) Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. *J Antimicrob Chemother* 62: 555-565.
177. Holden KL, Stein DA, Pierson TC, Ahmed AA, Clyde K, et al. (2006) Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3' stem-loop structure. *Virology* 344: 439-452.
178. Raviprakash K, Liu K, Matteucci M, Wagner R, Riffenburgh R, et al. (1995) Inhibition of dengue virus by novel, modified antisense oligonucleotides. *J Virol* 69: 69-74.
179. Zhang XG, Mason PW, Dubovi EJ, Xu X, Bourne N, et al. (2009) Antiviral activity of geneticin against dengue virus. *Antiviral Res* 83: 21-27.
180. Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, et al. (2009) Development of a broad-spectrum antiviral with activity against Ebola virus. *Antiviral Res* 83: 245-251.
181. Abd Kadir SL, Yaakob H, Mohamed Zulkifli R (2013) Potential anti-dengue medicinal plants: a review. *J Nat Med* 67: 677-689.
182. Tang LI, Ling AP, Koh RY, Chye SM, Voon KG (2012) Screening of anti-dengue activity in methanolic extracts of medicinal plants. *BMC Complement Altern Med* 12: 3.
183. Koishi AC, Zanello PR, Bianco ÉM, Bordignon J, Nunes Duarte dos Santos C (2012) Screening of Dengue virus antiviral activity of marine seaweeds by an in situ enzyme-linked immunosorbent assay. *PLoS One* 7: e51089.
184. Padilla-S L, Rodriguez A, Gonzales MM, Gallego-G JC, Castano-O JC (2014) Inhibitory effects of curcumin on dengue virus type 2-infected cells in vitro. *Arch Virol* 159: 573-579.
185. Lee SH, Tang YQ, Rathkrishnan A, Wang SM, Ong KC, et al. (2013) Effects of cocktail of four local Malaysian medicinal plants (*Phyllanthus* spp.) against dengue virus 2. *BMC Complement Altern Med* 13: 192.
186. Lin LT, Chen TY, Lin SC, Chung CY, Lin TC, et al. (2013) Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. *BMC Microbiol* 13: 187.
187. Ahmad N, Fazal H, Ayaz M, Abbasi BH, Mohammad I, et al. (2011) Dengue fever treatment with *Carica papaya* leaves extracts. *Asian Pac J Trop Biomed* 1: 330-333.

This article was originally published in a special issue, **Advances in Drug Development: Novel Antiviral Agents** handled by Editor(s). Dr. Erik de Leeuw, University of Maryland Baltimore School of Medicine, USA